Review
Version 1
Preserved in Portico This version is not peer-reviewed
Immunomodulators Acting on COVID-19: Actual Knowledge and Perspectives
Version 1
: Received: 5 July 2020 / Approved: 5 July 2020 / Online: 5 July 2020 (17:01:31 CEST)
How to cite: Durán, N.; Fávaro, W. J. Immunomodulators Acting on COVID-19: Actual Knowledge and Perspectives. Preprints 2020, 2020070090. https://doi.org/10.20944/preprints202007.0090.v1 Durán, N.; Fávaro, W. J. Immunomodulators Acting on COVID-19: Actual Knowledge and Perspectives. Preprints 2020, 2020070090. https://doi.org/10.20944/preprints202007.0090.v1
Abstract
Since the outbreak of SARS CoV-2 infection (Covid-19), healthcare professionals worldwide have been trying to find disease management and control alternatives to encourage immunotherapies. Immunotherapy is an efficient therapeutic option used against comparable viral contaminations such as MERS-CoV and SARS-CoV. The aim of the current study is to assess the existing knowledge associated with SARS-CoV-2 immunotherapy. Information available in published articles and their quality highlights the importance of following strict scientific rules for clinical outcomes. Thus, these studies have shown enough data to confirm that immunomodulation is the main topic investigated in research about Covid-19 therapy. Therefore, it is possible saying that immunotherapy is certainly the appropriate option against this virus.
Keywords
COVID-19; Immunotherapy; Immunomodulator; Antibody; Plasma; Immunoglobulins
Subject
Biology and Life Sciences, Immunology and Microbiology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment